284 related articles for article (PubMed ID: 33665733)
1. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis?
Jackson T; Darwish M; Cho E; Nagatomo K; Osman H; Jeyarajah DR
Abdom Radiol (NY); 2021 Jul; 46(7):3179-3183. PubMed ID: 33665733
[TBL] [Abstract][Full Text] [Related]
2. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
3. Should
Babazadeh NT; Schlund DJ; Cornelius T; Singh JS; Tierney JF; Chen M; Keutgen XM
World J Surg; 2020 Feb; 44(2):604-611. PubMed ID: 31576440
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
5. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
7. Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors.
Apitzsch J; Verburg FA; Mottaghy F; Heinzel A
Diagn Interv Radiol; 2021 Jul; 27(4):573-579. PubMed ID: 34313245
[TBL] [Abstract][Full Text] [Related]
8. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
9. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT.
Kunz WG; Eschbach RS; Stahl R; Kazmierczak PM; Bartenstein P; Rominger A; Auernhammer CJ; Spitzweg C; Ricke J; Cyran CC
Cancer Imaging; 2018 Sep; 18(1):34. PubMed ID: 30236163
[TBL] [Abstract][Full Text] [Related]
11. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.
Cleary JO; Yeung J; McMeekin H; Wilhelm T; Wagner T
Nucl Med Commun; 2016 Nov; 37(11):1197-205. PubMed ID: 27399848
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
13. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
17. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
Kunikowska J; Lewington V; Krolicki L
Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
[TBL] [Abstract][Full Text] [Related]
18. Use of MRI and Ga-68 DOTATATE for the detection of neuroendocrine liver metastases.
Haider M; Jiang BG; Parker JA; Bullock AJ; Goehler A; Tsai LL
Abdom Radiol (NY); 2022 Feb; 47(2):586-595. PubMed ID: 34757459
[TBL] [Abstract][Full Text] [Related]
19. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM
Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600
[TBL] [Abstract][Full Text] [Related]
20.
Delpassand ES; Ranganathan D; Wagh N; Shafie A; Gaber A; Abbasi A; Kjaer A; Tworowska I; Núñez R
J Nucl Med; 2020 Jun; 61(6):890-896. PubMed ID: 31924723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
